Armour Thyroid Monitoring Schedule: Labs & Exams

How Armour Thyroid Works (and Why Monitoring Differs)

Armour Thyroid is a porcine-derived desiccated thyroid extract containing both levothyroxine (T4) and liothyronine (T3) in an approximate 4.2:1 ratio by weight [1]. Each grain (60 mg) delivers roughly 38 mcg T4 and 9 mcg T3. This differs from synthetic levothyroxine monotherapy, which relies entirely on peripheral conversion of T4 to T3 via deiodinase enzymes.

The direct T3 content creates a pharmacokinetic pattern that standard monitoring protocols were not designed to capture. T3 has a half-life of approximately 1 day compared to T4's 7-day half-life, producing a transient free T3 peak 2 to 4 hours after ingestion [2]. This peak can transiently suppress TSH below reference range even when the patient is clinically euthyroid. The 2014 American Thyroid Association (ATA) guidelines acknowledge that TSH may be lower in patients on combination T4/T3 therapy without signifying overtreatment [3]. Monitoring only TSH in these patients leads to unnecessary dose reductions and symptom recurrence.

A 2013 randomized crossover trial by Hoang et al. (N=70) compared desiccated thyroid extract to levothyroxine over 16 weeks per arm. Both achieved similar TSH normalization, but 49% of participants preferred DTE versus 19% preferring levothyroxine (P = 0.001) [1]. Patients on DTE lost an average of 1.5 kg more. The study drew labs in the morning before dosing, a protocol that should be replicated in clinical practice.

Baseline Labs Before Starting Armour Thyroid

Before prescribing the first dose, order a complete thyroid panel and metabolic baseline. This establishes the reference point against which all future values will be compared.

The minimum baseline panel includes TSH, free T4, free T3, total T3, and thyroid peroxidase (TPO) antibodies. TPO status matters because Hashimoto's thyroiditis patients may experience antibody-driven fluctuations that affect dose stability [4]. The AACE/ACE 2012 clinical practice guidelines recommend including a lipid panel at baseline, since hypothyroidism elevates LDL cholesterol and effective treatment should produce a measurable lipid improvement within 8 to 12 weeks [5].

Add a CBC and comprehensive metabolic panel. Hypothyroidism causes macrocytic anemia in some patients, and tracking MCV improvement confirms adequate thyroid hormone delivery to bone marrow. For patients over 60, obtain a baseline ECG. The direct T3 load from Armour can increase heart rate by 5 to 10 bpm, and pre-existing conduction abnormalities warrant closer cardiac monitoring [3].

Document resting heart rate, blood pressure, weight, and a validated symptom score (the Zulewski clinical score or ThyPRO-39 questionnaire) at the initial visit. These non-laboratory measures anchor treatment decisions when lab values appear discordant with clinical presentation.

The 6-Week Recheck: First Critical Interval

Six weeks after starting Armour Thyroid (or after any dose change), repeat the core thyroid panel: TSH, free T4, and free T3. This interval allows TSH to reach new steady state, which requires approximately 5 half-lives of T4 (5 x 7 days = 35 days) [6].

Draw blood in the fasting state, before the morning dose. If the patient took their Armour dose that morning, free T3 will reflect the absorption peak rather than trough, rendering the result uninterpretable for dosing decisions. The Hoang et al. protocol specified morning draws before dosing [1], and this timing should be standard practice.

At 6 weeks, expect TSH to fall but possibly not normalize if the starting dose was conservative (15 to 30 mg). A TSH between 1.0 and 3.0 mIU/L with free T3 in the upper third of the reference range and resolution of symptoms represents the therapeutic target for most adults. The 2012 AACE guidelines suggest a TSH goal of 0.45 to 4.12 mIU/L for general hypothyroidism management, while noting that individual targets may be tighter based on symptoms [5].

If TSH remains above 4.0 mIU/L with persistent symptoms, increase the dose by 15 mg (one quarter grain) and recheck in another 6 weeks. Do not increase by more than 30 mg at a time in patients over 50 or those with coronary artery disease.

Ongoing Monitoring: The Stable-State Protocol

Once the patient achieves a stable dose with symptom resolution and acceptable labs, transition to a 6-to-12-month monitoring interval. The ATA recommends annual thyroid function testing for patients on stable replacement therapy [3].

Every 6-month visit should include TSH, free T4, free T3, symptom reassessment, weight, and resting heart rate. Annual visits add a lipid panel and consideration of bone density screening for at-risk populations.

"For patients taking combination T4/T3 preparations, clinicians should measure serum free T3 in addition to TSH to adequately assess thyroid status," states the 2012 AACE/ACE guideline document [5]. Omitting free T3 in a patient on Armour Thyroid is an incomplete evaluation.

Several triggers warrant returning to the 6-week recheck cycle: dose adjustment, pregnancy, initiation of estrogen therapy (which increases thyroxine-binding globulin), starting medications that interfere with absorption (calcium, iron, proton pump inhibitors), significant weight change exceeding 10%, or new symptoms suggesting over- or undertreatment [3].

Free T3 Interpretation on Desiccated Thyroid

Free T3 monitoring separates competent NDT management from protocol-driven errors. On levothyroxine alone, free T3 is less informative because it simply reflects peripheral conversion. On Armour, free T3 directly measures the exogenous T3 contribution and correlates more tightly with symptom resolution.

A 2018 retrospective analysis published in Thyroid (Idrees et al., N=156) found that patients on desiccated thyroid had free T3 levels 15 to 20% higher than those on levothyroxine at equivalent TSH values, without increased adverse cardiovascular events over a mean follow-up of 3.2 years [7]. This confirms that a free T3 in the upper quarter of normal range is expected, not alarming, in NDT-treated patients.

The practical interpretation framework:

• Free T3 in the upper third of range with TSH 0.5 to 2.5 and symptom resolution: optimal, maintain dose.
• Free T3 above range with TSH below 0.1 and tachycardia: reduce dose by 15 mg and recheck at 6 weeks.
• Free T3 mid-range with TSH 1.0 to 3.0 but persistent fatigue: consider that cellular T3 utilization may differ from serum levels; trial a 15 mg increase with close monitoring.
• Free T3 below mid-range with TSH above 3.0: clearly underdosed, increase by 15 to 30 mg.

Draw timing is non-negotiable. A free T3 drawn 2 hours post-dose may read 40 to 60% higher than the true trough value [2].

TSH Suppression: When It Does and Does Not Matter

TSH below 0.4 mIU/L in a patient on Armour Thyroid requires clinical context rather than reflexive dose reduction. The pituitary responds to free T3 directly, and even small amounts of exogenous T3 can suppress TSH disproportionately to the actual tissue thyroid status.

The Framingham Heart Study offspring cohort (N=2,575) found that subclinical hyperthyroidism (TSH 0.1 to 0.4 mIU/L) was associated with a 3.1-fold increased risk of atrial fibrillation over 10 years in adults over 60 [8]. This risk applies to exogenous suppression as well. For patients under 60 without cardiac risk factors, a TSH of 0.3 to 0.5 mIU/L with normal free T3 and no symptoms of excess may be acceptable. For patients over 60 or with atrial fibrillation risk, maintain TSH above 0.4 mIU/L.

"Overt or subclinical hyperthyroidism should be avoided, particularly in older patients and those at risk for cardiovascular disease or osteoporosis," states the 2014 ATA guideline for hypothyroidism treatment [3].

When TSH is suppressed below 0.1 mIU/L, always reduce the dose regardless of symptom status. This degree of suppression carries bone density and cardiac rhythm risk that outweighs symptomatic benefit [8].

Bone Density and Cardiac Monitoring

Long-term TSH suppression accelerates bone loss in postmenopausal women. A meta-analysis by Blum et al. (2015) encompassing 5,458 patients found that TSH below 0.5 mIU/L was associated with a 1.9-fold increased risk of hip fracture [9]. For postmenopausal women on Armour Thyroid, order DXA scanning at baseline and every 2 years if TSH runs persistently below 1.0 mIU/L.

Cardiac monitoring involves resting heart rate at every visit (target 60 to 85 bpm), annual ECG for patients over 60, and Holter monitoring if palpitations develop. The direct T3 delivery makes heart rate the earliest and most sensitive clinical marker of overtreatment. A resting heart rate consistently above 90 bpm warrants dose reassessment even if labs appear acceptable.

For premenopausal women and men under 50, bone density screening follows standard osteoporosis guidelines unless TSH is persistently suppressed below 0.3 mIU/L, in which case DXA every 2 to 3 years is reasonable.

Special Populations: Pregnancy, Elderly, and Cardiac Patients

Pregnancy demands the most aggressive monitoring. TSH should be checked at confirmation of pregnancy, then every 4 weeks through the first trimester, every 6 weeks in the second trimester, and once during the third trimester [10]. The ATA's 2017 pregnancy guidelines recommend trimester-specific TSH ranges: first trimester 0.1 to 2.5 mIU/L, second trimester 0.2 to 3.0 mIU/L, third trimester 0.3 to 3.5 mIU/L. Most patients require a 30 to 50% dose increase during pregnancy due to rising TBG and expanded plasma volume. However, many endocrinologists prefer switching pregnant patients to levothyroxine monotherapy because the T3 component does not cross the placenta efficiently [3].

In patients over 65, start at the lowest available dose (15 mg) and increase no faster than 15 mg every 8 weeks rather than 6. Check TSH, free T3, and an ECG at each titration step. The cardiac risk of overshoot in this population outweighs the urgency of rapid symptom resolution.

For patients with established coronary artery disease, some clinicians avoid desiccated thyroid entirely due to the T3 bolus effect. If Armour is used despite cardiac history, monitor with serial ECGs, maintain resting heart rate below 80 bpm, and keep TSH above 1.0 mIU/L. Any new chest pain, dyspnea, or arrhythmia should prompt immediate dose reduction and cardiology referral.

Practical Lab Draw Protocol

Standardize the lab draw to eliminate variability between visits. Instruct patients to take their Armour Thyroid dose at the same time daily (morning, 30 to 60 minutes before eating). Schedule lab draws for early morning, fasting, before that day's dose. This means the last dose was taken the previous morning, approximately 24 hours before the draw.

If a patient inadvertently takes their dose before the draw, document this and interpret the free T3 value as artificially elevated. Do not make dose changes based on post-dose free T3 levels. Reschedule the draw if a critical dosing decision depends on it.

For patients splitting their Armour dose (taking half in the morning and half in early afternoon, a practice some clinicians use to smooth the T3 curve), draw labs before the morning dose. The split-dose approach reduces T3 peak-to-trough fluctuation by approximately 30% according to pharmacokinetic modeling, though no randomized trial has confirmed clinical superiority [2].

Record the exact time of last dose and time of blood draw in the chart. Across a patient's longitudinal record, inconsistent draw timing creates the illusion of dose instability where none exists.

Medication Interactions Requiring Extra Monitoring

Several common medications alter thyroid hormone absorption or metabolism and require a return to the 6-week recheck protocol when initiated, discontinued, or changed in dose.

Calcium carbonate, ferrous sulfate, and aluminum-containing antacids bind thyroid hormone in the gut. Separate administration by at least 4 hours. When any of these are started, recheck TSH and free T3 at 6 weeks [3]. Proton pump inhibitors reduce gastric acidity needed for Armour tablet dissolution. Estrogen-containing oral contraceptives and hormone replacement therapy increase TBG, reducing free hormone availability; expect a 20 to 30% dose increase requirement [6].

Rifampin and phenytoin accelerate hepatic T4 and T3 clearance through cytochrome P450 induction. Patients starting these drugs need thyroid rechecks at 4 and 8 weeks. Amiodarone contains 75 mg of iodine per 200-mg tablet and causes both hypo- and hyperthyroidism; monitor TSH monthly for the first 6 months of co-administration.

Annual Comprehensive Review Checklist

At the yearly comprehensive visit, review:

1. TSH, free T4, free T3 (drawn before morning dose, fasting)
2. Lipid panel (LDL should have normalized with adequate treatment)
3. CBC (MCV should be normal; persistent macrocytosis suggests B12 deficiency, common in autoimmune thyroid disease)
4. Vitamin D 25-OH (hypothyroid patients have higher prevalence of deficiency)
5. TPO antibodies (trending titers may predict dose instability in Hashimoto's)
6. Resting heart rate, blood pressure, weight
7. Symptom questionnaire (ThyPRO-39 or equivalent)
8. Medication reconciliation (new interacting drugs?)
9. DXA results review (if applicable)
10. ECG (if over 60 or cardiac history)

This checklist ensures no monitoring element is overlooked across the year. The cost of comprehensive annual labs is minimal compared to the cost of undetected over- or undertreatment.

A patient stably dosed on Armour Thyroid 90 mg daily with a TSH of 1.2 mIU/L, free T3 of 3.8 pg/mL (range 2.0 to 4.4), free T4 of 1.0 ng/dL (range 0.8 to 1.8), resting heart rate of 72 bpm, and symptom resolution needs only annual monitoring with the full checklist above. Any deviation from this stable pattern triggers the 6-week reassessment cycle.